JPRN-UMIN000006877已完成未知
Phase II study of XELIRI with bevacizumab as second-line therapy for metastatic colorectal cancer -Beyond Progression Disease of capecitabine and bebacizumab - - Phase II study of XELIRI + Bevacizumab as second-line therapy for metastatic colorectal cancer
Gunma University Graduate School0 个研究点目标入组 30 人开始时间: 2011年12月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Phase II study of XELIRI and bevacizumab as second-line therapy in patients with metastatic colorectal cancerJPRN-UMIN000008668Kitasato university school of medicine38
尚未招募
2 期
Phase II study of XELIRI and High-dose bevacizumab as second-line therapy in patients with metastatic colorectal cancercolorectal cancerJPRN-UMIN000008425Yokohama Rosai Hospital38
招募中
2 期
Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine,oxaliplatin plus bevacizumab for metastatic colorectal cancerJPRN-UMIN000011679Chubu Clinical Oncology Group25
已完成
2 期
Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine, irinotecan plus bevacizmab for metastatic colorectal cancernresectable metastatic or recurrent colorectal cancerJPRN-UMIN000011552Chubu Clinical Oncology Group (CCOG)25
已完成
2 期
A Phase II Study of Tri-weekly XELIRI with Bevacizumab for patient with unresectable or recurrent Colorectal Cancer as first -line chemotherapy.Colorectal CancerJPRN-UMIN000006070Kyushu Study group of Clinical Cancer35